Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission enjoy certified a hottest suggestion in championship of REMICADE(R) (infliximab) allowing for the handwriting of rigid, helpful Crohn's bug (CD) contained by means of pediatric patients aged 6 to 17 years, who have not counter to demonstrated psychiatric abet plus a corticosteroid, an immunomodulator and opening nutrition therapy, or who be vindictive to, or have contraindications for, such therapy. REMICADE has be studied with the sole purpose in concoction close by conventional immunosuppressive therapy. This approbation follow a happy feelings granted in March by the Committee for Medicinal Products for Human Use (CHMP) for the European Medicines Agency (EMEA).
"Crohn's disease vitally impact the factor of lean by of cultural group hazard from this incident," said Salvatore Cucchiara, M.D., Department of Pediatrics, Gastrointestinal Motility and Endoscopy Unit, University of Naples. "Infliximab provide physician with a new treatment picking that address the personal aspect of this difficult-to-treat disease in the pediatric population." REMICADE be the original and only biologic therapy approved in the EU for the treatment of pediatric CD, a severe condition that create inflammation of the gastrointestinal tract, with ease consequent in symptom such by mode of diarrhea, frenzy, abdominal shooting pain, make stirring for injury and in several patients, delayed progress and stunted stock up.
"This approval recognize the unique handiness of REMICADE as it is the first and only biologic therapy going spare to children suffering with Crohn's disease in Europe, who in times gone by have permanent therapy option," said Robert J. Spiegel, M.D., chief medical officer, Schering-Plough Research Institute.
In May 2006, the United States Food and Drug Administration (FDA) approved REMICADE for pediatric patients with relatively to rigorously active CD who have had an unsatisfactory rejoinder to conventional therapy. REMICADE be first approved in the U.S. for grown Crohn's disease in 1998 and next for adult ulcerative colitis in 2005.
The refuge and efficacy of REMICADE across all indication have been economically established in clinical trial perform times gone by 14 years and through commercial submit yourself to with nearly 925,000 patients treat entire across all indications.
The marker new structure will deliver in physicians to administer a 5 mg/kg intravenous infusion of REMICADE over a 2-hour circumstance follow by other 5 mg/kg infusion dose at two and six weeks after the first infusion, afterwards all eight weeks thereafter. Some patients may oblige a shorter dose break to prolong clinical lead, while for others a longer dosing interval may be adequate. Available facts perform upon not support further REMICADE treatment in pediatric patients not respond inwardly the first 10 weeks of treatment.
Clinical Trial Information: REACH The approval was remnant on data from the Phase III REACH (a Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF Monoclonal Antibody REMICADE in Pediatric Subjects with Moderate to Severe Crohn's Disease) investigation. In the REACH trial, 112 patients (6 to 17 years of age; all compulsory to be acceptance 6-MP, AZA or MTX; 35% receiving corticosteroids) with pleasant to severe, active Crohn's disease (median PCDAI of 40) and an inadequate response to conventional therapies received 5 mg/kg infliximab at weeks 0, 2, and 6.
Patients review by the investigator to be in clinical response at week 10 be randomized and received 5 mg/kg infliximab at any q8 weeks or q12 weeks as a charge treatment regimen. Patients who vanished clinical response during maintenance treatment could receive infliximab at a difficult frequency or dose.
The amount of study in clinical response at week 10 was 88.4% (99/112). The proportion of subjects realize clinical remission at week 10 was 58.9% (66/112). At week 30, the proportion of subjects in clinical remission was higher in the q8 week (59.6%, 31/52) than the q12 week maintenance treatment faction (35.3%, 18/51; p0.013). At week 54, the proportion of subjects in clinical remission was 55.8% (29/52) and 23.5% (12/51) in the q8 week and q12 week maintenance group, respectively (p0.001).
Thirty-two evaluable pediatric patients (9 in the q8 week and 23 in the q12 week maintenance group) lost response and then received infliximab at a higher dose or more on a regular proof.
Twenty-four of these thirty-two patients (75.0%) regain clinical response.
Of the 22 subjects that had fistulas at baseline, 63.6% (14/22), 59.1% (13/22) and 68.2% (15/22) were in complete fistula response at weeks 10, 30 and 54, respectively, in the multiparty q8 week and q12 weeks maintenance group.
In compound, statistically and clinically of great magnitude improvements in quality of life and increase, above and beyond as a significant drop in corticosteroid employ, were observed.
The subsequent adverse dealings were report more generally in pediatric Crohn's disease patients in the REACH trial than in adult Crohn's disease patients: anaemia (10.7%), blood in stool (9.7%), leukopenia (8.7%), flush (8.7%), viral infectivity (7.8%), neutropenia (6.8%), prepare fracture (6.8%), bacterial infection (5.8%), and respiratory tract allergic hypersensitivity (5.8%).
Other taking sides consideration are discuss down below.
About Pediatric Crohn's Disease Crohn's disease is a entrenched ailment that causes inflammation of the gastrointestinal tract, typically resulting in symptoms such as diarrhea, fever, abdominal pain and weight loss.
Children with Crohn's disease may also experience delayed development and stunted growth. Although it can jumble with any monarchy of the gastrointestinal tract from the orifice to the anus, it selected commonly affect the short intestine and/or colon.
About REMICADE REMICADE is a monoclonal antibody that definitely target TNF-alpha, which has been shown to comedy a role in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC) and psoriasis (PsO).
REMICADE was approved in the EU in 1999 for the treatment of severe, active CD in patients who have not responded even with a replete and all within your rights programme of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. REMICADE also is symbolize for the treatment of fistulizing, active CD in patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
For RA patients in the EU, REMICADE, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the lay down on a base in blue-collar manoeuvre in patients with active disease when the response to disease-modifying drugs, including methotrexate, has been inadequate, and in patients with severe, active and laissez-faire disease not previously treated with methotrexate or other DMARDs. In these merciful populations, a reduction in the rate of the increase of reciprocal lay misuse to, as measured by X-ray, has been demonstrated.
In the EU, REMICADE is also indicated for the treatment of AS in patients who have severe axial symptoms, elevated serological marker of inflammatory entertainment. and who have responded too little to conventional therapy. REMICADE is also approved for the treatment of active and progressive PsA in patients when the response to preceding disease-modifying anti-rheumatic drugs therapy has been inadequate. REMICADE should be administered in combination with MTX or alone in patients who musical intolerance to MTX or for whom MTX is contraindicated. REMICADE is also approved in the EU for the treatment of moderate to severe plaque psoriasis in patients who slipshod to respond to, or have a contraindication to, or are intolerant of other systemic therapy including cyclosporine, MTX or PUVA (psoralen plus ultraviolet A light).
In February 2006, REMICADE was approved in the EU for the treatment of moderately-to- severely active UC in patients who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies. This approval made REMICADE the first and only biologic therapy approved to delight moderate-to-severe UC in the EU.
REMICADE is the only anti-TNF biologic therapy available as an IV means. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered head-on by caregivers in the clinic or department environment. In RA (3 mg/kg), CD (5 mg/kg), PsA (5 mg/kg), psoriasis (5 mg/kg) and UC (5 mg/kg), REMICADE is a two-hour infusion administered every 8 weeks, following a tenet induction regimen that require treatment at weeks 0, 2 and 6. As a upshot, REMICADE patients may require as few as six treatment all year. In AS (5 mg/kg), REMICADE is a two-hour infusion administered every 6 to 8 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6.
In watchfully elected patients with RA who have tolerate three pilot two-hour infusions of REMICADE, prudence may be given to administering subsequent infusions over a period of not lower numeral than one hour. Shortened infusions at doses greater than 6 mg/kg have not been studied.
Furthermore, if an RA patient has an inadequate response or lose response after initial treatment with REMICADE, consideration may be given to increase the dose step-wise by generally 1.5 mg/kg, competent to a maximum of 7.5 mg/kg every 8 weeks. Alternatively, overseeing of 3 mg/kg as commonly as every 4 weeks may be considered. If adequate response is achieve, patients should be unremitting on the selected dose or dose frequency. Continued therapy should be carefully check in patients who show no testimony of profitable benefit within the first 12 weeks of treatment or after the dose has been familiar.
REMICADE treatment is to be initiate and supervise by qualified physicians worldly erudite in the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, psoriatic arthritis or psoriasis. REMICADE infusions should be administered by qualified healthcare professionals ruined in to detect any infusion associated issues. Patients treated with REMICADE should be given a bag flier and a special alert card.
Centocor discovered REMICADE and has grateful marketing rights to the supplies in the United States. Schering-Plough market REMICADE in all pastoral out-of-doors of the United States, bar in Japan and parts of the Far East where on earth Tanabe Seiyaku, Ltd. markets the product and in China where Xian- Janssen markets REMICADE.
Important Safety Information There are reports of weighty infection, including tuberculosis (TB), sepsis and pneumonia. Some of these infections have been lethal. Tell your standard practitioner if you have had recent or long-gone transport to wispy to empire with TB. Your doctor will measure up to you for TB and contrive a TB try-out. If you have inactive (inactive) TB, your doctor should gain going TB treatment back you instigation REMICADE.
REMICADE can demean your facility to rebel infections, hence if you are prone to or have a what went before of infections, or come along any signs of an infection such as fever, fatigue, cough, respiratory tract infection or swelling, red or bumpy rind while taking REMICADE, make clear to your doctor minus difficulty. Also, tell your doctor if you are programmed to receive a vaccine or if, you have lived in a locality where histoplasmosis or coccidioidomycosis is undivided.
Reports of a manner of blood cancer give the name lymphoma in patients on REMICADE or other TNF blockers are in danger of extinction but yield up more often than anticipated for people taken as a whole. People who have been treated for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, or psoriatic arthritis for a extended time, principally those with outstandingly active disease may be more prone to develop lymphoma. Cancers, except lymphoma, have also been reported. Rarely, children and young-looking adults who have been treated for Crohn's disease with REMICADE in combination with azathioprine or 6-mercaptopurine have industrialized a rare type of lymphoma, hepatosplenic T cell lymphoma (HSTL), that often grades in extermination. If you lift REMICADE or other TNF blockers, your chance for sprouting lymphoma or other cancer may increase. You should also tell your doctor if you have had or develop lymphoma or other cancers or if you have a lung disease called chronic obstructive pulmonary disease (COPD).
Many people with heart inert loss should not take REMICADE; so prior to treatment you should question any heart condition with your doctor. Tell your doctor right away if you develop new or drop symptoms of heart failure (such as brevity of breath, improvement of your ankles or foot, or hasty weight gain).
Reactivation of hepatitis B virus has been reported in patients who are possessor of this virus and are taking TNF blockers, such as REMICADE. Some of these cases have been fatal. Tell your doctor if you know or high regard as you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as passion not a hundred percent, impecunious appetite, lethargy, fever, skin absolute and/or joint pain.
There have been rare cases of serious liver harm in people taking REMICADE, some fatal. Tell your doctor if you have liver worries and bond your doctor in a jiffy if you develop symptoms such as jaundice (yellow skin and eyes), calm down taupe urine, right-sided abdominal pain, fever, or severe fatigue.
Blood disorder have been reported, some fatal. Tell your doctor if you develop practicable signs of blood disorders such as insistent fever, bruising, bleeding, or pastiness while taking REMICADE. Nervous net disorders have also been reported. Tell your doctor if you have or have had a disease that affects the obsessed system, or if you experience any insufficiency of feeling, poor quality, tingling, optical disturbances or seizure while taking REMICADE.
Allergic reaction, some severe have been reported during or after infusions with REMICADE. Signs of an allergic reaction indemnity hives, solidity breathing, relish chest pain, significant or scant blood coercion, swelling of obverse and hand, and fever or chills. Tell your doctor if you have experienced a severe allergic reaction. The most common annoyed effects of REMICADE are: respiratory infections, such as sinus infections and throbbing gorge, headache, rash, coughing, and tummy painful.
For complete EU prescribe statistics, satisfy drop by About Centocor Centocor is harness the propulsion of world-leading research and biomanufacturing to deliver advanced biomedicines that develop patients' inhabit. Centocor has already bring inventiveness to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.
The world foremost light in monoclonal antibody crop and technology, Centocor has brought accusing biologic therapies to patients suffering from debilitating immune disorders. Centocor, Inc.
is a utterly personal subsidiary of Johnson & Johnson.
This clench delivery enclose "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statement are based on contemporary expectations of impending events. If underlying assumption prove vague or unknown risk or uncertainties materialize, actual results could ebb and flow materially from Johnson & Johnson's expectations and projection. Risks and uncertainties include general industry stipulations and challenge; economic conditions, such as seasoning rate and coinage barter rate fluctuations; industrial advance and patent attain by competitor; nudge inbuilt in new product development, including obtain regulatory approvals; reclaimed and foreign strength care recover and governmental decree and regulations; and trend toward health care outlay containment. A further catalogue and bumf of these risks, uncertainties and other factor can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year terminated December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at or on direct from Johnson & Johnson. Johnson & Johnson do not embark upon to update any forward-looking statements suitably of new information or future events or development.
About Schering-Plough Schering-Plough is a worldwide science-based health care company with leading prescription, consumer and animal health products. Through interior research and teamwork with partner, Schering-Plough unearth, develop, manufacture and markets advanced pills therapies to collect momentous medical requirements. Schering-Plough's imagine is to earn the trust of the physicians, patients and regulars serve by its approximately 33,500 people in a nimbus the world. The company is based in Kenilworth, N.J., and its Web set down is SCHERING-PLOUGH DISCLOSURE NOTICE: The information here press release contains in almost clearly "forward-looking" statements within the purpose of the Private Securities Litigation Reform Act of 1995, including statements related to the approval of REMICADE for CD in the EU and the forthcoming approachable market for REMICADE. Forward-looking statements label to expectations or forecasts of future events. Schering-Plough does not suppose the condition to update any forward-looking notice. Many factors could cause actual results to vary materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, exclusive rights and other academic chattels haven, current and future characterized, generic or over-the-counter competition, the regulatory action, and any developments following regulatory approval, among other uncertainties. For further list and a seminar of risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's first quarter 10-Q.
Schering-Plough
healthy bones - read about